Revolution Medicines, Inc. RVMD
13 trading plans running, 59 Form 144 notices for $161.3M
10-Q, 10-K and Form 144What RVMD's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From May 22, 2026 to Nov 17, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in |
|---|---|---|---|
| Margaret Horn, J.D Chief Operating Officer |
Adopted 10b5-1 plan | Sep 9, 2026 | 10-Q Nov 4, 2026 |
| Flavia Borellini a member of our board of directors |
Adopted 10b5-1 plan | Aug 20, 2026 | 10-Q Nov 4, 2026 |
| Steve Kelsey, M.D President, Research and Development |
Adopted 10b5-1 plan | Aug 17, 2026 | 10-Q Nov 4, 2026 |
| Jack Anders Chief Financial Officer |
Adopted 10b5-1 plan | Aug 12, 2026 | 10-Q Nov 4, 2026 |
| Elizabeth Anderson a member of our board of directors |
Adopted 10b5-1 plan | Jun 23, 2026 | 10-Q Nov 4, 2026 |
| Anthony Mancini, Chief Global Commercialization Officer |
Adopted 10b5-1 plan | Jun 15, 2026 | 10-Q Aug 5, 2026 |
| Alan Sandler, M.D Chief Development Officer |
Adopted 10b5-1 plan | Jun 14, 2026 | 10-Q Aug 5, 2026 |
| Steve Kelsey, M.D President, Research and Development |
Adopted 10b5-1 plan | Jun 12, 2026 | 10-Q Aug 5, 2026 |
| Jeff Cislini Senior Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | May 22, 2026 | 10-Q Aug 5, 2026 |
| Mark A. Goldsmith President and Chief Executive Officer and Chair of the Board of Directors |
Adopted 10b5-1 plan | May 22, 2026 | 10-Q Aug 5, 2026 |
| Sushil Patel a member of our board of directors |
Adopted 10b5-1 plan | Mar 30, 2026 | 10-Q May 6, 2026 |
| Jack Anders Chief Financial Officer |
Adopted 10b5-1 plan | Mar 24, 2026 | 10-Q May 6, 2026 |
| Margaret Horn Chief Operating Officer |
Adopted 10b5-1 plan | Mar 12, 2026 | 10-Q May 6, 2026 |
| Wei Lin M.D., our Chief Medical Officer |
Adopted 10b5-1 plan | Dec 16, 2025 | 10-K Feb 25, 2026 |
| Mark A. Goldsmith M.D., Ph.D., our President and Chief Executive Officer and Chair of the Board of Directors |
Adopted 10b5-1 plan | Nov 25, 2025 | 10-K Feb 25, 2026 |
| Jeff Cislini Senior Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | Mar 13, 2025 | 10-Q May 7, 2025 |
| Margaret Horn Chief Operating Officer |
Adopted 10b5-1 plan | Mar 7, 2025 | 10-Q May 7, 2025 |
| Steve Kelsey M.D., FRCP, FRCPath, President, Research and Development |
Adopted 10b5-1 plan | Feb 28, 2025 | 10-Q May 7, 2025 |
| Wei Lin M.D., our Chief Medical Officer |
Adopted 10b5-1 plan | Dec 23, 2024 | 10-K Feb 26, 2025 |
| Mark A. Goldsmith M.D., Ph.D., our President and Chief Executive Officer and Chair of the Board of Directors |
Adopted 10b5-1 plan | Dec 19, 2024 | 10-K Feb 26, 2025 |
| Jack Anders Chief Financial Officer |
Adopted 10b5-1 plan | Dec 16, 2024 | 10-K Feb 26, 2025 |
| Wei Lin M.D., Chief Medical Officer |
Ended 10b5-1 plan | Aug 2, 2024 | 10-Q Aug 7, 2024 |
| Barbara Weber M.D., a member of our board of directors |
Adopted 10b5-1 plan | May 29, 2024 | 10-Q Aug 7, 2024 |
| Margaret Horn J.D., Chief Operating Officer |
Adopted 10b5-1 plan | Mar 22, 2024 | 10-Q Aug 7, 2024 |
| Wei Lin M.D., the Company’s Chief Medical Officer |
Adopted 10b5-1 plan | Mar 21, 2024 | 10-Q May 8, 2024 |
| Jeff Cislini Senior Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | Mar 20, 2024 | 10-Q Aug 7, 2024 |
| Steve Kelsey M.D., FRCP, FRCPath, President, Research and Development |
Adopted 10b5-1 plan | Mar 15, 2024 | 10-Q Aug 7, 2024 |
| Jack Anders Chief Financial Officer |
Adopted 10b5-1 plan | Mar 14, 2024 | 10-Q Aug 7, 2024 |
| Sushil Patel Ph.D., a member of our board of directors |
Adopted 10b5-1 plan | Sep 7, 2023 | 10-Q Aug 7, 2024 |
| Jack Anders Chief Financial Officer |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 8, 2023 |
| Jeff Cislini Senior Vice President, General Counsel and Secretary |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 8, 2023 |
| Margaret Horn J.D., Chief Operating Officer |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 8, 2023 |
| Mark A. Goldsmith M.D., Ph.D., Chair of the Board, Chief Executive Officer and President |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 8, 2023 |
| Steve Kelsey M.D., FRCP, FRCPath, President, Research and Development |
Adopted 10b5-1 plan | May 31, 2023 | 10-Q Aug 8, 2023 |
Show the other 26 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 12, 2026 | JACK LEE ANDERS Officer |
35,750 | $6.9M |
| Sep 29, 2026 | ALAN SANDLER Officer |
6,309 | $1.3M |
| Sep 25, 2026 | ANTHONY MANCINI Officer |
9,363 | $1.9M |
| Sep 24, 2026 | ANTHONY MANCINI Officer |
587 | $112K |
| Sep 22, 2026 | Elizabeth Anderson Director |
15,080 | $2.9M |
| Sep 18, 2026 | ANTHONY MANCINI Officer |
1,764 | $347K |
| Sep 15, 2026 | Mancini Anthony Officer |
2,377 | $484K |
| Sep 15, 2026 | Cislini Jeff Officer |
3,272 | $667K |
| Sep 15, 2026 | Sandler Alan B Officer |
331 | $67K |
| Sep 15, 2026 | Anders Jack Officer |
3,939 | $803K |
| Sep 15, 2026 | Kelsey Stephen Michael Officer |
5,415 | $1.1M |
| Sep 15, 2026 | Horn Margaret A Officer |
4,830 | $984K |
| Sep 15, 2026 | Goldsmith Mark A Officer, Director |
13,603 | $2.8M |
| Sep 11, 2026 | STEPHEN KELSEY Officer |
92,531 | $18.8M |
| Sep 10, 2026 | ANTHONY MANCINI Officer |
15,448 | $3.2M |
| Aug 31, 2026 | Lorence H Kim Affiliate |
73,090 | $15.2M |
| Aug 21, 2026 | THE JONATHAN GOLDSMITH REVOCABLE TRUST Director, Officer |
3,000 | $635K |
| Aug 21, 2026 | THE REBECCA GOLDSMITH REVOCABLE TRUST Director, Officer |
3,000 | $635K |
| Aug 21, 2026 | MARK A GOLDSMITH Director, Officer |
80,000 | $16.9M |
| Aug 21, 2026 | JEFFREY TODD CISLINI Officer |
75,894 | $16.1M |
| Jun 29, 2026 | SUSHIL PATEL Director |
5,580 | $1.0M |
| Jun 24, 2026 | JACK ANDERS Officer |
20,000 | $3.4M |
| Jun 15, 2026 | Mancini Anthony Officer |
4,211 | $648K |
| Jun 15, 2026 | Cislini Jeff Officer |
1,656 | $255K |
| Jun 15, 2026 | MARGARET A HORN Officer |
90,000 | $13.8M |
| Jun 15, 2026 | Anders Jack Officer |
2,653 | $408K |
| Jun 15, 2026 | Kelsey Stephen Michael Officer |
4,071 | $626K |
| Jun 15, 2026 | Horn Margaret A Officer |
3,486 | $536K |
| Jun 15, 2026 | GOLDSMITH MARK A Officer, Director |
9,772 | $1.5M |
| Jun 11, 2026 | MARGARET A HORN Officer |
10,000 | $1.4M |
| May 26, 2026 | ANTHONY MANCINI Officer |
3,121 | $473K |
| Apr 27, 2026 | ANTHONY MANCINI Officer |
3,120 | $422K |
| Apr 15, 2026 | MARK A GOLDSMITH Director, Officer |
120,000 | $17.6M |
| Mar 26, 2026 | Mancini Anthony Officer |
37,450 | $3.6M |
| Mar 19, 2026 | JEFFREY TODD CISLINI Officer |
1,163 | $114K |
| Mar 13, 2026 | Cislini Jeff Officer |
2,053 | $204K |
| Mar 13, 2026 | Wei Lin Officer |
2,288 | $228K |
| Mar 13, 2026 | Wang Xiaolin Officer |
2,282 | $227K |
| Mar 13, 2026 | Anders Jack Officer |
2,134 | $213K |
| Mar 13, 2026 | Kelsey Stephen Michael Officer |
3,901 | $389K |
| Mar 13, 2026 | Horn Margaret A Officer |
4,722 | $470K |
| Mar 13, 2026 | GOLDSMITH MARK A Officer, Director |
13,261 | $1.3M |
| Mar 2, 2026 | JONATHAN GOLDSMITH REVOCABLE TRUST Director, Officer |
3,000 | $306K |
| Mar 2, 2026 | THE REBECCA GOLDSMITH REVOCABLE TRUST Director, Officer |
3,000 | $306K |
| Mar 2, 2026 | MARK A GOLDSMITH Director, Officer |
30,000 | $3.1M |
| Jan 21, 2026 | JEFFREY TODD CISLINI Officer |
908 | $106K |
| Jan 7, 2026 | MARGARET A HORN Officer |
75,000 | $6.0M |
| Jan 7, 2026 | JACK LEE ANDERS Officer |
10,000 | $798K |
| Dec 12, 2025 | Cislini Jeff Officer |
2,614 | $203K |
| Dec 12, 2025 | Anders Jack Officer |
3,017 | $235K |
| Dec 12, 2025 | Kelsey Stephen Michael Officer |
5,296 | $412K |
| Dec 12, 2025 | Horn Margaret A Officer |
4,711 | $367K |
| Dec 12, 2025 | GOLDSMITH MARK A Officer, Director |
14,964 | $1.2M |
| Nov 25, 2025 | J H GOLDSMITH & M A GOLDSMITHCO-TTEE JONATHAN GOLDSMITH REV TRU/A/D 8/16/2023 Director, Officer |
3,000 | $221K |
| Nov 25, 2025 | THE REBECCA GOLDSMITH REVOCABLE TRUST Director, Officer |
3,000 | $221K |
| Nov 25, 2025 | MARK A GOLDSMITH Director, Officer |
60,000 | $4.4M |
| Nov 25, 2025 | JACK LEE ANDERS Officer |
5,418 | $399K |
| Nov 18, 2025 | MARK A GOLDSMITH Director, Officer |
20,000 | $1.4M |
| Nov 18, 2025 | JEFFREY TODD CISLINI Officer |
13,388 | $926K |
Show the other 51 notices
From the Form 144 XML filed with the SEC, since Nov 18, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RVMD/export.csv") into a cell.